MA-based MitoSense secures $3.5million in seed funding. Lead the funding round was Caydan Capital Partners. The funding will be used by the company to further its cutting-edge research in the field of mitochondrial organelle transplantation (MOTTM).
MitoSense is a biotechnology business that focuses on developing treatments for neurodegenerative illnesses and is committed to improving mitochondrial health through novel therapeutics and research.
Read also – WA-based Oleria Secures $33.1M in Series A Round Funding
Numerous neurodegenerative illnesses, including Huntington’s, Parkinson’s, multiple sclerosis, and others, may be treated with this technology.
About MitoSense
MitoSense are a research and development firm that possesses patent-pending technology that is uniquely licenced. Their technique replenishes mitochondria to combat disease, especially neurological illnesses like Parkinson’s, Alzheimer’s, and ALS.
Read also – Conn.-based Kusari Secures $8m in Pre-Seed & Seed Funding
